Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition including venlafaxine for treating depression and relevant diseases

A composition and drug technology, applied in the directions of drug combinations, active ingredients of heterocyclic compounds, pharmaceutical formulations, etc.

Inactive Publication Date: 2007-03-21
陈彦方
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Excellent results have been published with the use of a pharmaceutical combination of lithium and mirtazapine, but the potentiation is not strong enough to select this pharmaceutical combination as the first choice for the treatment of depressive disorders (Bruijn et al. Journal Clin. Psychlatry, Vol. 59, pp. 657-663, 1998)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: Self-defense burial test

[0037] The marble burial test was developed as a preclinical test for anxiolytic activity (Andrews and Broekkamp (1993): "Procedures to identify anxiolytic or anxiogenic agents", Behavior Behavioral Neuroscience, editor: A Sahgal, pp. 37-54, IRL Press, Oxford). In the marble burial test, mice are placed in a novel environment containing 25 marbles (arranged on a sawdust surface). The reduction in the number of marble blocks buried by the mice was inferred to be an anxiolytic-like / antidepressant-like effect.

[0038] Sulpiride alone reduced the number of buried marbles with an ED50 of 2.16 mg.kg administered by subcutaneous injection (S.C.) -1 . Administration of venlafaxine alone reduced the number of marble burials with an ED50 of 5.5 mg.kg by S.C. -1 . Another series of three separate experiments was performed during which a range of S.C. sulpiride doses (0, 0.1, 0.3, 1, 3 mg.kg -1 ) co-administered three single doses of ven...

Embodiment 2

[0040] Embodiment 2: EEG test

[0041] The purpose of this study was to characterize the effects of sulpiride alone and co-administration of venlafaxine and sulpiride on sleep-wake behavior in rats. For this purpose, the effect of venlafaxine on itself was additionally studied. Sleep-wake behavior was analyzed by using electroencephalographic (EEG) recordings, electromyographic (EMG) recordings and by recording motor index. Based on these signals, sleep-wake behavior is automatically divided into 6 levels every 2 seconds: active wakefulness, passive wakefulness, light sleep, deep sleep, intermediate sleep stages, and rapid eye movement (REM) sleep (Ruigt et al.: Large A large scale automated system for rat sleep staglng. I. Methodology and technical aspects - ((Electroenceph.and Clin.Neurophysiol. ); 1989; 73:52-64).32 adult male Sprague-Dawley rats (Harlan olac, Bicester, UK, weighing 250-800g) were carried out in various experiments simultaneously, and they were divided in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses one kind of medicine composition for treating depression and relevant diseases, and the medicine composition includes certain amount of venlafaxine or its medicinal salt or solvate, certain amount of sulpiride or its solvate, and one or several kinds of medicine carrier or excipient. The medicine composition has such amount of sulpiride and venlafaxine as to result in synergistic effect. The medicine composition is used in treating depression and relevant diseases, and has less untoward reaction.

Description

technical field [0001] The present invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition comprising venlafaxine for treating depression and related diseases. Background technique [0002] Central nervous system disorders such as depression and anxiety are diseases that affect people of all ages. Although many drugs exist to treat these diseases, currently available treatments are often still inadequate. It is noteworthy that in approximately one-third of all subjects with depression or anxiety there was no definitive treatment outcome and recovery was slow in the active treatment group, with effects occurring as early as 2 weeks after initiation of medication. Venlafaxine is disclosed in various literatures for the treatment of depression and anxiety, and US Patent No. 5,530,013 (Husbands et al.) claims the use of venlafaxine to induce cognitive enhancement. U.S. Patent No. 5,506,270 (Upton et al.) claims the use of venlafaxine fo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/135A61K31/40A61P25/24
Inventor 陈彦方
Owner 陈彦方
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com